by Alexander Kulik, Ian G. Burwash, Varun Kapila, Thierry G

Slides:

Advertisements

Similar presentations

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Advertisements

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does Elevated C-Reactive Protein Increase Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Atrial Tissue Fibrosis Identified.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Emerging Role of Exercise Testing and Stress.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Healthy Lifestyle and Decreasing Risk of Heart Failure.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Spironolactone inhibits the transcardiac extraction.

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Management of mitral regurgitation. See legend for Fig

Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.

Tomislav Mihaljevic, MD, Edward R

From: Functional Status and Quality of Life After Transcatheter Aortic Valve ReplacementA Systematic Review Ann Intern Med. 2014;160(4): doi: /M

Ruyun Jin, MD, Gary L. Grunkemeier, PhD, Albert Starr, MD

Women, Bleeding, and Coronary Intervention

From: Independent Predictors and Outcomes of Unanticipated Early Postoperative Tracheal Intubation after Nonemergent, Noncardiac Surgery Anesthes. 2011;115(1):44-53.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Copyright © 2009 American Medical Association. All rights reserved.

Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,

Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.

Relationship of Physical Activity and Body Mass Index to the Risk of Hypertension: A Prospective Study in Finland by Gang Hu, Noël C. Barengo, Jaakko Tuomilehto,

Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.

Circ Cardiovasc Qual Outcomes

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

by Mario Gössl, Garvan C. Kane, William Mauermann, and David R. Holmes

Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,

Energy Loss Index in Aortic Stenosis

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

by Clarisse Toledo, George Thomas, Jesse D

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,

The persistent problem of new-onset postoperative atrial fibrillation: A single-institution experience over two decades Jeanne Shen, BS, Shelly Lall,

Moderate chronic kidney disease and left ventricular hypertrophy after aortic valve replacement for aortic valve stenosis Umberto Benedetto, MD, Giovanni.

Dileep Raman et al. JACEP 2017;3:

Johannes Steiner et al. JACC 2017;70:

Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery Jeremy J. Pereira, MB, Krzysztof Balaban, MD,

John M. Fallon, MD, Joseph P. DeSimone, MD, J

Mild-to-moderate functional tricuspid regurgitation in patients undergoing mitral valve surgery Sun Kyun Ro, MD, Joon Bum Kim, MD, Sung Ho Jung, MD,

Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study Thomas Decker Christensen, MD, PhD, Flemming Skjøth,

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

Wesley T. O’Neal et al. JACEP 2016;2:

Ruyun Jin, MD, Gary L. Grunkemeier, PhD, Albert Starr, MD

Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,

New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery Giovanni Filardo, PhD, MPH, Cody Hamilton,

Molly E. Waring, PhD, Jane S

Clinical and echocardiographic outcomes after repair of mitral valve bileaflet prolapse due to myxomatous disease Vincent Chan, MD, MPH, Marc Ruel, MD,

Vitality Measured as Self-reported Energy Level and Clinical Outcomes in Hemodialysis Patients: The Japanese Dialysis Outcomes and Practice Pattern Study.

Long-Term Durability of Bicuspid Aortic Valve Repair

Alexander Kulik, MD, Manal Al-Saigh, MD, Vincent Chan, MD, Roy G

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

Connie W. Tsao et al. JCHF 2016;4:

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Two internal thoracic artery grafts are better than one

Effect of the prosthesis–patient mismatch on long-term clinical outcomes after isolated aortic valve replacement for aortic stenosis: A prospective observational.

David A. Goodkin, MD, Eric W

Forest plot showing the association between center-level characteristics and death-censored technique failure after adjusting for age, sex, race, body.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Connie W. Tsao et al. JCHF 2016;4:

Associations between type of MI and incident HF

Guidance for the use of bilateral internal thoracic arteries according to survival benefit across age groups Umberto Benedetto, MD, PhD, Mohamed Amrani,

Defining Patient-Prosthesis Mismatch and Its Effect on Survival in Patients With Impaired Ejection Fraction David A. Cotoni, DO, Robert T. Palac, MD,

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes Steven M. Brunelli, Ravi Thadhani,

Prosthesis–patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: Effect on survival,

Rick A. Nishimura et al. JACC 2017;70:

Late incidence and determinants of stroke after aortic and mitral valve replacement Marc Ruel, MD, MPH, Roy G Masters, MD, Fraser D Rubens, MD, Pierre.

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Volume 16, Issue 7, Pages (July 2019)

A – Demographic, Anthropometric and Clinical correlates of plasma NT-proBNP levels stratified by race: Multivariable Regression Results (Multivariable.

Presentation transcript:

Long-Term Outcomes After Valve Replacement for Low-Gradient Aortic Stenosis by Alexander Kulik, Ian G. Burwash, Varun Kapila, Thierry G. Mesana, and Marc Ruel Circulation Volume 114(1 suppl):I-553-I-558 July 4, 2006 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Survival (A) and the incidence of persistent or recurrent CHF (B) in patients with and without LGAS after AVR. *Hazard ratio adjusted for left ventricular function, age, atrial fibrillation, preoperative NYHA functional class, coronary artery disease, smoking, and insulin-dependent diabetes mellitus. Figure 1. Survival (A) and the incidence of persistent or recurrent CHF (B) in patients with and without LGAS after AVR. *Hazard ratio adjusted for left ventricular function, age, atrial fibrillation, preoperative NYHA functional class, coronary artery disease, smoking, and insulin-dependent diabetes mellitus. AVR indicates, aortic valve replacement; CHF, congestive heart failure; CI, confidence interval; LGAS, low-gradient aortic stenosis. Alexander Kulik et al. Circulation. 2006;114:I-553-I-558 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Impact of PPM on survival (A) and the incidence of persistent or recurrent CHF (B) after AVR in patients with LGAS. *Hazard ratio adjusted for LV function, age, atrial fibrillation, preoperative heart failure functional class, coronary artery disease, smoking, and insulin-dependent diabetes mellitus. Figure 2. Impact of PPM on survival (A) and the incidence of persistent or recurrent CHF (B) after AVR in patients with LGAS. *Hazard ratio adjusted for LV function, age, atrial fibrillation, preoperative heart failure functional class, coronary artery disease, smoking, and insulin-dependent diabetes mellitus. IEOA indicate indexed effective orifice area; PPM, prosthesis–patient mismatch. Alexander Kulik et al. Circulation. 2006;114:I-553-I-558 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Impact of PPM on LV mass regression after AVR among patients with and without LGAS. LV indicates left ventricle.*P=0.037 refers to the comparison of PPM vs no PPM in LGAS patients. †P=0.1 refers to the comparison of PPM vs no PPM in no LGAS patients. Figure 3. Impact of PPM on LV mass regression after AVR among patients with and without LGAS. LV indicates left ventricle.*P=0.037 refers to the comparison of PPM vs no PPM in LGAS patients. †P=0.1 refers to the comparison of PPM vs no PPM in no LGAS patients. Alexander Kulik et al. Circulation. 2006;114:I-553-I-558 Copyright © American Heart Association, Inc. All rights reserved.